Treatment-related adverse events, including fatal toxicities, in patients with extensive-stage small-cell lung cancer receiving adjuvant programmed cell death 1 …
FCA de Moraes, A de OM Lôbo, VKT Sano, FA Kelly… - Clinical Oncology, 2024 - Elsevier
Abstract Background/Aims The safety profile of programmed cell death 1 (PD-
1)/programmed cell death ligand 1 (PD-L1) inhibitors when associated with chemotherapy …
1)/programmed cell death ligand 1 (PD-L1) inhibitors when associated with chemotherapy …
Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis
FCA de Moraes, M Kreuz, ICA de Lara, AOM Lôbo… - BMC cancer, 2024 - Springer
Background Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin
cancer characterized by high rates of metastasis. Emerging evidence suggests that PD …
cancer characterized by high rates of metastasis. Emerging evidence suggests that PD …
Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized …
FCA de Moraes, E Pasqualotto… - European Journal of …, 2025 - Springer
Background The optimal treatment for resectable Non-Small Cell Lung Cancer (NSCLC)
remains under investigation, particularly about its effectiveness across different ethnicities …
remains under investigation, particularly about its effectiveness across different ethnicities …
Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis
D Huang, S Li, Y Bai, Y Wang - BMC cancer, 2024 - Springer
Background Currently, several randomized controlled trials (RCTs) have been conducted to
investigate the efficacy of combining immune checkpoint inhibitors (ICIs) with chemotherapy …
investigate the efficacy of combining immune checkpoint inhibitors (ICIs) with chemotherapy …
The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients
FCA de Moraes, RYU Sudo, MEC Souza… - BMC cancer, 2024 - Springer
Background Female gynecological cancers represent a serious public health problem, with
1,398,601 new diagnoses and 671,875 deaths per year worldwide. Antipsychotics are often …
1,398,601 new diagnoses and 671,875 deaths per year worldwide. Antipsychotics are often …
Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different …
AK Abushanab, MT Mustafa, MT Mousa… - Expert Review of …, 2025 - Taylor & Francis
ABSTRACT Background Immune checkpoint inhibitors (ICIs) are currently the primary
approach for managing NSCLC. However, numerous combination therapies are currently …
approach for managing NSCLC. However, numerous combination therapies are currently …
Association between ovarian tumors and exposure to assisted reproductive technologies and ovarian stimulation: a systematic review and meta-analysis
AOM Lôbo, V Morbach, FA Kelly… - Archives of Gynecology …, 2024 - Springer
Methods: We performed a comprehensive search of PubMed, Embase, and Web of Science
databases for case–control and cohort studies that investigated ART and ovulation induction …
databases for case–control and cohort studies that investigated ART and ovulation induction …
PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis
FCA de Moraes, VKT Sano, BL Silva, ALS Silva… - Journal of …, 2025 - Springer
Abstract Background and Objective Gastric cancer (GC) remains a leading cause of
morbidity and mortality worldwide. The current standard of care involves neoadjuvant …
morbidity and mortality worldwide. The current standard of care involves neoadjuvant …
Identifying immunotherapeutic strategies for children with medulloblastoma
Z Abbas - 2024 - research-repository.uwa.edu.au
Medulloblastoma is the most common malignant paediatric brain tumour, and clinical
outcomes for group 3 medulloblastoma remain poor, prompting the need for new therapies …
outcomes for group 3 medulloblastoma remain poor, prompting the need for new therapies …